- Featured Product
- KD/KO Validated
PD-L1/CD274 (C-terminal) Polyclonal antibody
PD-L1/CD274 (C-terminal) Polyclonal Antibody for IF, IHC, IP, WB, ELISA
Cat no : 28076-1-AP
Validation Data Gallery
|Positive WB detected in||IFN gamma treated A549 cells, mouse heart tissue, rat heart tissue, MDA-MB-231 cells, human placenta tissue, THP-1 cells|
|Positive IP detected in||human placenta tissue|
|Positive IHC detected in||human tonsillitis tissue, human placenta tissue, human breast cancer tissue, human lung cancer tissue, human cervical cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||human tonsillitis tissue|
|Western Blot (WB)||WB : 1:300-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:500-1:2000|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
28076-1-AP targets PD-L1/CD274 (C-terminal) in WB, IP, IHC, IF, ELISA applications and shows reactivity with Human, mouse, rat samples.
|Tested Reactivity||Human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||PD-L1/CD274 (C-terminal) fusion protein Ag27557|
|Full Name||CD274 molecule|
|Calculated molecular weight||290 aa, 33 kDa|
|Observed molecular weight||45-50 kDa|
|GenBank accession number||BC074984|
|Gene ID (NCBI)||29126|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis.
What is the molecular weight of PD-L1?
Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa).
What are the isoforms of PD-L1?
According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions.
What is the subcellular localization and tissue specificity of PD-L1?
It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues.
What is the function of PD-L1 in immune responses?
PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681).
How can PD-L1's implication in cancer be used as a drug target?
In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).
|Product Specific Protocols|
|WB protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-AP||Download protocol|
|IHC protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-AP||Download protocol|
|IF protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-AP||Download protocol|
|IP protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer.
Clin Cancer Res
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Cancer Immunol Immunother
Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS.
Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment.
J Exp Clin Cancer Res
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.